Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Financing Activities (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Cash from Financing Activities for 12 consecutive years, with $75.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 7410.3% to $75.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.4 million through Dec 2025, down 87.52% year-over-year, with the annual reading at $76.4 million for FY2025, 87.52% down from the prior year.
  • Cash from Financing Activities hit $75.1 million in Q4 2025 for Viking Therapeutics, up from $480000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $606.0 million in Q1 2024 to a low of -$5.0 million in Q1 2022.
  • Historically, Cash from Financing Activities has averaged $48.6 million across 5 years, with a median of $753500.0 in 2024.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 22770.21% in 2022 and later plummeted 840.0% in 2023.
  • Year by year, Cash from Financing Activities stood at $47000.0 in 2021, then surged by 22770.21% to $10.7 million in 2022, then tumbled by 98.25% to $188000.0 in 2023, then surged by 431.91% to $1.0 million in 2024, then skyrocketed by 7410.3% to $75.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for VKTX at $75.1 million in Q4 2025, $480000.0 in Q3 2025, and $507000.0 in Q2 2025.